(NASDAQ: AVTX) Avalo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.
Avalo Therapeutics's earnings in 2026 is -$78,259,000.On average, 13 Wall Street analysts forecast AVTX's earnings for 2026 to be -$115,175,115, with the lowest AVTX earnings forecast at -$171,515,005, and the highest AVTX earnings forecast at -$44,266,568. On average, 9 Wall Street analysts forecast AVTX's earnings for 2027 to be -$98,981,641, with the lowest AVTX earnings forecast at -$152,755,551, and the highest AVTX earnings forecast at -$55,273,390.
In 2028, AVTX is forecast to generate -$78,449,246 in earnings, with the lowest earnings forecast at -$113,450,029 and the highest earnings forecast at -$44,984,404.